The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?

• Published in: Pharmaceutical research Vol. 28; no. 4; pp. 934 - 937
• Main Authors: Pirnay, Jean-Paul, De Vos, Daniel, Verbeken, Gilbert, Merabishvili, Maia, Chanishvili, Nina, Vaneechoutte, Mario, Zizi, Martin, Laire, Geert, Lavigne, Rob, Huys, Isabelle, Van den Mooter, Guy, Buckling, Angus, Debarbieux, Laurent, Pouillot, Flavie, Azeredo, Joana, Kutter, Elisabeth, Dublanchet, Alain, Górski, Andrzej, Adamia, Revaz
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01-04-2011; Springer Nature B.V; American Association of Pharmaceutical Scientists
• Subjects: Anti-Bacterial Agents; Anti-Bacterial Agents - therapeutic use; Antibiotics; Bacterial Infections; Bacterial Infections - drug therapy; Bacteriophages; Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Biotechnology; Commentary; Drug Industry; Drug resistance; Drug therapy; Humans; Life Sciences; Medical Law; Pharmacology; Pharmacology/Toxicology; Pharmacy; bacterial infection; antibiotic resistance; drugs; bacteriophages; phage therapy
• ISSN: 0724-8741; 1573-904X
• DOI: 10.1007/s11095-010-0313-5

Efforts to develop antibiotics that are not resistance to bacterial infections are discussed from a pharmacological perspective, focusing on phage therapy. Phage therapy has great potential in some (niche) clinical contexts, but as with antibiotic treatment, there are likely to be important evolutionary consequences if it is implemented widely and without sufficient oversight.